Patents by Inventor Antonio Lanzavecchia

Antonio Lanzavecchia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10420834
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: September 24, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 10414817
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 17, 2019
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20190248874
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 15, 2019
    Inventor: Antonio Lanzavecchia
  • Publication number: 20190233504
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Application
    Filed: March 22, 2019
    Publication date: August 1, 2019
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Ebony BENJAMIN, Leslie WACHTER, Andy YUAN, Josephine Mary MCAULIFFE, Davide CORTI, Antonio LANZAVECCHIA
  • Patent number: 10294292
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: May 21, 2019
    Inventors: Nicole Kallewaard-LeLay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
  • Patent number: 10273288
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 30, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The United States of America, as represented by the Secretary of the Army, Humabs Biomed SA
    Inventors: Nancy Sullivan, Sabue Mulangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Publication number: 20190071489
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.
    Type: Application
    Filed: November 14, 2018
    Publication date: March 7, 2019
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The Government of the United States, as represented by the Secretary of the Army, Humabs BioMed SA
    Inventors: Nancy Sullivan, Sabue Malangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Publication number: 20180371062
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: July 2, 2018
    Publication date: December 27, 2018
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 10160795
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: December 25, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The United States of America as represented by the Secretary of the Army, Humabs BioMed SA
    Inventors: Nancy Sullivan, Sabue Mulangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Publication number: 20180327800
    Abstract: A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 15, 2018
    Inventor: Antonio LANZAVECCHIA
  • Publication number: 20180291088
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virususing the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virusinfection in a subject.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 11, 2018
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The Government of the United States as represented by the Secretary of the Army, Humabs BioMed SA
    Inventors: Nancy Sullivan, Sabue Mulangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Patent number: 10040845
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 7, 2018
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Publication number: 20180186897
    Abstract: The present invention provides a pharmaceutical composition, for example a vaccine, which comprises a RIFIN, which is able to bind to a mutated LAIR-1 fragment, which broadly binds to erythrocytes infected with Plasmodium falciparum. Such a RIFIN may be useful in the prevention and/or treatment of malaria.
    Type: Application
    Filed: June 24, 2016
    Publication date: July 5, 2018
    Inventors: Antonio Lanzavecchia, Roger Geiger, Luca Piccoli
  • Publication number: 20180179274
    Abstract: The present invention provides a protein comprising a mutated LAIR-1 fragment, which broadly binds to erythrocytes infected with Plasmodium falciparum. The protein comprising the mutated LAIR-1 fragment may be useful in the prevention and/or treatment of malaria. The present invention furthermore provides a nucleic acid encoding a mutated LAIR-1 fragment, a vector comprising such a nucleic acid as well as a respective pharmaceutical composition.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 28, 2018
    Inventors: Antonio Lanzavecchia, Joshua Tan, Abdi Abdirahman, Kathrin Pieper, Luca Piccoli, Peter Charles Bull
  • Publication number: 20180142014
    Abstract: The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non- overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
    Type: Application
    Filed: April 29, 2015
    Publication date: May 24, 2018
    Inventors: Davide CORTI, Antonio LANZAVECCHIA, Luca PICCOLI
  • Publication number: 20180086819
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: September 27, 2017
    Publication date: March 29, 2018
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Publication number: 20180008697
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: December 24, 2015
    Publication date: January 11, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Publication number: 20170334972
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 23, 2017
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Patent number: 9803000
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 31, 2017
    Assignee: Institute of Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 9796772
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 24, 2017
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa MacAgno